Palvella Therapeutics (PVLA) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 10, 2026, to be held virtually at 11:00 AM EST.

• Proxy materials and 10-K for fiscal year ending December 31, 2025, are available online for review and voting.

• Shareholders are encouraged to review all proxy materials before voting and can opt for electronic delivery to support environmental initiatives.

Voting matters and shareholder proposals

• Election of three Class III director nominees to serve until 2029: George M. Jenkins, Todd C. Davis, and John Doux, M.D.

• Ratification of Ernst & Young as independent registered public accounting firm for fiscal year 2026.

• Advisory vote on executive compensation and preferred frequency of future say-on-pay votes.

• Proposal to amend the 2024 Equity Incentive Plan to increase authorized shares by 750,000.

• Approval to adjourn the meeting if insufficient votes are present for Proposal 5.

Board of directors and corporate governance

• Board recommends voting FOR all director nominees and FOR Proposals 2, 3, 5, and 6, and 1 YEAR for Proposal 4.